(1) Subjects who have any active autoimmune disease or history of autoimmune disease, (2) Subjects who received immunosuppressive therapy by using immunosuppressant, or systemic or absorbable topic hormone therapy (temprednisone or other therapeutic hormones with a dosage >10 mg/day) within 14 days prior to the administration of the studied drug, (3) Severe allergic reaction to other monoclonal antibodies, (4) Women in pregnancy or lactation, (5) Human immunodeficiency virus (HIV) infection, (6) Subjects with abnormal coagulation, bleeding tendency or undergoing thrombolysis or anticoagulation, (7) Subjects with any known hereditary or acquired bleeding and thrombotic tendencies (e.g. hemophiliacs, coagulation disorders or thrombocytopenia), (8) Subjects who have previously received other PD-1 antibody therapy or other immunotherapy for PD-1/PD-L.

(1) Subjects who have any active autoimmune disease or history of autoimmune disease, (2) Subjects who received immunosuppressive therapy by using immunosuppressant, or systemic or absorbable topic hormone therapy (temprednisone or other therapeutic hormones with a dosage >10 mg/day) within 14 days prior to the administration of the studied drug, (3) Severe allergic reaction to other monoclonal antibodies, (4) Women in pregnancy or lactation, (5) Human immunodeficiency virus (HIV) infection, (6) Subjects with abnormal coagulation, bleeding tendency or undergoing thrombolysis or anticoagulation, (7) Subjects with any known hereditary or acquired bleeding and thrombotic tendencies (e.g. hemophiliacs, coagulation disorders or thrombocytopenia), (8) Subjects who have previously received other PD-1 antibody therapy or other immunotherapy for PD-1/PD-L.